Insiders · PVLA

John Doux

Director at Palvella Therapeutics, Inc. (PVLA) since April 2026

John Doux has filed 3 insider reports with the SEC since April 2026, as director at Palvella Therapeutics, Inc. (PVLA). The latest filing, on June 12, 2026, reports grant or award at Palvella Therapeutics, Inc. (PVLA).

Filings
3
Companies
1
Bought on market
None
Sold on market
None

Companies where John Doux is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Palvella Therapeutics, Inc. logo
PVLA
Palvella Therapeutics, Inc.
Directorsince April 2026$144.35Jun 12, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare John Doux with

Other insiders at the same companies

Questions about John Doux

What is John Doux's role at Palvella Therapeutics, Inc.?
John Doux reports to the SEC as director at Palvella Therapeutics, Inc. (PVLA), according to the latest filing on June 12, 2026.
Has John Doux bought or sold stock recently?
No open-market purchases or sales by John Doux are on file. The filings report grant or award.
How do I get alerts when John Doux files?
Follow John Doux on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by John Doux (SEC CIK 0001912574). Totals count each trade once, skipping amendments whose original is on file, from Apr 15, 2026 on. View on SEC EDGAR